# Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer

> **NCT00268463** · PHASE3 · TERMINATED · sponsor: **NSABP Foundation Inc** · enrollment: 22 (actual)

## Conditions studied

- Colorectal Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** floxuridine
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00268463
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** The study was terminated due to low accrual.
- **Last updated:** 2013-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268463, "Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00268463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*